Tuesday, June 03, 2014 6:06:14 PM
The real increase will come in 2016 and beyond, with Otrexup being on the market for 3 years and gaining share, plus epipen and QST just hitting the market. All ATRS products will require time to ramp up sales as these aren't life-saving drugs that jump off the shelves. Ultimately QST is the biggest hitter in the ATRS pipeline from a revenue potential standpoint. But again, it won't launch until the back half of 2016 or even early 2017.
FEATURED Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • ELMGF • Sep 10, 2024 11:00 AM